The investigation of MCP-1 as a biomarker in primary nephropathy is limited, primarily encompassing certain glomerular diseases; however, it has demonstrated significant value in crescentic glomerulonephritis,chronic glomerulonephritis and AKI. Here, CCL2 is linked to crescentic glomerulonephritis.